We don't focus on cost or sales price. Our only priority is to select patented raw materials in highly bioavailable forms and ensure optimal preservation for maximum effectiveness.

Adding many strains without a direct link to the targeted problem may be unnecessary or even detrimental to overall effectiveness.

Compatibility between strains is essential because some can interact antagonistically.

The same principle applies to UFCs (Colony Forming Units), for which an excess number can be unnecessary and sometimes increase costs without any real additional benefit.

We're closely monitoring scientific advances in next-generation probiotics: genetically modified, antimicrobial, immunomodulatory, and even those capable of acting on microRNAs. As soon as they're approved, we'll be among the first to offer them to you.